Monoclonal Antibody News and Research

RSS

Monoclonal antibodies (MAbs) are produced from a single B cell clone and can bind to a single type of antigen binding site. MAbs are homogenous antibodies that cannot form lattices with monomeric proteins as they can bind to only a single epitope on the antigen. Developed in the 1970s, MAbs can be produced against any given substance. Thus they can be used to detect and purify any substance of interest. This has made MAbs a powerful tool of molecular biology, biochemistry, and medicine.

Broad-spectrum neutralizing antibody mAb-39 targets conserved S2 epitope in SARS-CoV-2

The ongoing COVID-19 pandemic caused by SARS-CoV-2 has caused serious damage to public health and the global economy, and one strategy to combat COVID-19 has been the development of broadly neutralizing antibodies for prophylactic and therapeutic use.

1 Mar 2024

Omalizumab boosts tolerance to multiple food allergies, study finds

A study in The New England Journal of Medicine shows omalizumab increases allergen tolerance in individuals with multiple food allergies, offering a promising standalone treatment option.

26 Feb 2024

Novel monoclonal antibody shows promise in targeting HER2-positive breast cancer cells

In a step forward for breast cancer treatment, researchers at Tohoku University have developed a novel monoclonal antibody which specifically targets a certain type of breast cancer cell.

19 Feb 2024

FDA approves omalizumab for food allergy reactions based on NIH research

Today's Food and Drug Administration approval of a supplemental biologics license for the monoclonal antibody omalizumab (Xolair) highlights the vital role of the National Institutes of Health-supported research that underpins the FDA decision.

16 Feb 2024

Combo of targeted and immunotherapy may boost NSCLC treatment by overcoming immune resistance and enhancing anti-tumor activity

Researchers evaluated rational combination treatment regimens for advanced/metastatic non-small-cell lung cancer (NSCLC).

15 Feb 2024

Combination therapy offers breakthrough in NSCLC treatment

A specific combination of targeted therapy and immunotherapy may better help patients with non-small cell lung cancer (NSCLC) overcome inherent immune resistance and reinvigorate anti-tumor activity, according to a new study led by a researcher from The University of Texas MD Anderson Cancer Center.

13 Feb 2024

Impact of nirsevimab immunization on pediatric RSV-related hospitalizations in Luxembourg

Respiratory syncytial virus (RSV) is one of the main reasons leading to hospitalization among young children worldwide and each year, an estimated 101,000 children below the age of 5 years die due to RSV infections.

30 Jan 2024

Rice scientists identify promising new immunological pathway to treat breast cancer bone metastases

Rice University researchers in the lab of chemist Han Xiao have identified a promising new immunological pathway to treat stubborn bone tumors, one of most prevalent forms of metastases in breast cancer patients.

24 Jan 2024

Calluna Pharma launches and announces EUR 75 million Series A financing to develop novel therapies for inflammatory and fibrotic diseases

Oxitope Pharma (Oxitope) and Arxx Therapeutics (Arxx), companies with a shared goal of leveraging the innate immune system to discover and develop disease modulating therapies, today announced their merger to form Calluna Pharma Inc. (Calluna).

From Calluna Pharma 24 Jan 2024

Annexin-A1 targeted therapy beats several cancers

A new study published in Nature's cancer journal Oncogene highlights the effectiveness of MDX-124, the first therapeutic drug to target annexin-A1, a protein which is overexpressed in several cancer types and promotes tumour progression.

19 Jan 2024

New blood test technique raises hopes for more sensitive and earlier cancer diagnosis

Tumors constantly shed DNA from dying cells, which briefly circulates in the patient's bloodstream before it is quickly broken down. Many companies have created blood tests that can pick out this tumor DNA, potentially helping doctors diagnose or monitor cancer or choose a treatment.

18 Jan 2024

CGRP antagonists and dietary changes show promise for migraine treatment

Review in "Medicina" explores advancements in migraine therapy, highlighting the role of CGRP antagonists and dietary interventions like ketogenic and low-glycemic diets in reducing migraine frequency and severity.

17 Jan 2024

New study finds maternal vaccine and monoclonal antibody effective against RSV in infants

The impact and cost-effectiveness of maternal vaccination (MV) to long-acting monoclonal antibody (la-mAB) therapy.

10 Jan 2024

New Omicron subvariants test vaccine limits, reveal unique infection challenges

Study reveals that the Omicron subvariants BA.2.86 and FLip show unique mutations and infectivity profiles, with BA.2.86 being highly infectious and resistant to most conventional antibodies, underscoring the need for updated vaccines.

9 Jan 2024

SARS-CoV-2 BA.2.86 shows increased lung targeting despite vaccine effectiveness

New research shows that the recently emerged BA.2.86 omicron subvariant of the virus that causes COVID-19 can be neutralized by bivalent mRNA vaccine-induced antibodies in the blood, which explains why this variant did not cause a widespread surge as previously feared.

8 Jan 2024

Bridging ideas to IND: Nona Biosciences' year of impact in biotechnology

Amidst a backdrop of industry-wide hurdles like inflation, talent scarcities, and stringent regulatory landscapes, Nona Biosciences is showing great promise as an emerging global leader in biotechnology.

From Nona BioSciences 19 Dec 2023

New vaccine strategy targets SARS-CoV-2's stable S2 subunit, offering broad protection against evolving variants

Study presents a new SARS-CoV-2 S2 subunit vaccine that elicits strong antibody responses against various sarbecovirus strains, including challenging variants like XBB.1.5, demonstrating its potential as a broadly effective and stable vaccine option.

18 Dec 2023

Antibody treatment shields transplant patients against COVID-19

New research from Cedars-Sinai's Comprehensive Transplant Center found that a monoclonal antibody treatment reduced the risk of COVID-19 in a large group of solid organ transplant patients who were administered the drug as a preventive measure against the disease.

18 Dec 2023

Small molecule applications of process Raman spectroscopy

In this interview, Kevin Broadbelt of Thermo Fisher Scientific discusses the small molecule applications of process Raman spectroscopy.

From Thermo Fisher Scientific – Portable and Handheld Raman Spectroscopy 11 Dec 2023

Promising candidate medication for preventing and reversing fentanyl-induced overdose

Researchers assessed CSX-1004, a monoclonal antibody (mAb), for its efficacy in reversing fentanyl overdose based on its high affinity for fentanyl, positive animal model results, and safe pharmacokinetic profile, positioning it as a potential solution in the opioid crisis.

7 Dec 2023